Medullary thyroid cancer (MTC) accounts for only approximately 5% of all thyroid cancers but confers a proportionately worse prognosis. In part because medullary thyroid cancer is such a rare malignancy, it has been a challenging disease to study within single institutions, even from high-volume hospitals that have expertise with MTC. The article in this issue of JAMA Surgery by Kuo et al1 is a population-based study of patients with medullary thyroid cancer, attempting to define risk factors associated with disease recurrence within the confines of a large statewide cancer registry.
Gosnell JE, Duh Q. Medullary Thyroid Carcinoma—We Should Do Better. JAMA Surg. 2018;153(1):59. doi:10.1001/jamasurg.2017.3894
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.